This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
AstraZeneca (AZN) – gets US FDA approval for Lumoxiti to treat hairy cell leukaemia, the first new treatment option in over 20 years. Closing price: 5,630p (Source: Company newswires)
JD Wetherspoon (JD) – FY like-for-like sales +5.0%, but revenues and op. profit towards bottom end of consensus, dividend unchanged. Closing price: 500p (Source: Company newswires)
FTSE Miners (BLT, RIO, AAL, GLEN, VED) – potentially sensitive to positive overnight China data, with August Industrial Production (+6.1% YoY) and Retail Sales growth (+9%) accelerating (consensus stable), although Fixed Asset Investment (+5.3%) fell to its lowest ever, potentially hindered by the threat of US tariffs.
FTSE Housebuilders (BDEV, BKG, PSN, BVS) – potentially sensitive to Bank of England Governor Carney’s warning to PM May’s Cabinet that a no-deal Brexit worst-case scenario could push the UK into recession, unemployment spike and house prices plunge 25-35%.
(Sources: Company newswires, Bloomberg, CNBC, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
|WM MORRISON SUPERMARKETS||MRW||-2.6%||1.0%||-3.9%|
|LEGAL & GENERAL||LGEN||0.6%||0.9%||-0.2%|
|SPORTS DIRECT INTERNATIONAL||SPD||2.4%||5.0%||1.7%|
|JD SPORTS FASHION||JD/||-3.7%||0.6%||-3.8%|
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.Prepared by Michael van Dulken, Head of Research